#USA #FDA #Rockville #OncoC4 #Cesalatamig

OncoC4 Secures FDA Fast Track Designation for Cesalatamig

OncoC4 Inc., a biopharmaceutical company specializing in innovative treatments for cancer and neurodegenerative diseases, has gained significant momentum in its quest to advance cancer care. The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to their novel PD-1/VEGF bispecific antibody, Cesalatamig (also known as AI-081). This designation is crucial as it supports expedited development for the treatment of patients battling non-small cell lung cancer (NSCLC) who have seen their condition progress after receiving PD-(L)1-targeted therapies or platinum-based chemotherapy.

Significance of Fast Track Designation

Dr. Yang Liu, Co-founder, CEO, and Chief Scientific Officer of OncoC4, remarked, “This designation reflects the clinical safety and efficacy signals we have seen in our global Phase 1/2 trials, BiPAVE-001 US and BiPAVE-001 China.” The fast track status not only allows for quicker access to treatment options for patients but also signifies the promise evidenced in preliminary trials. OncoC4 plans to swiftly transition into phase 3 development, focusing on patients with PD-(L)1-refractory or resistant NSCLC and exploring additional indications for their burgeoning therapeutic.

The BiPAVE-001 Trials

The BiPAVE-001 trials, encompassing Phase 1 and Phase 2 stages, are focused on assessing Cesalatamig's safety, efficacy, and pharmacokinetics among patients with advanced cancer. The design is segmented into two parts:

• - Phase 1: This involves dose escalation and expansion to identify optimal dosing strategies.
• - Phase 2: This will focus on dose optimization through various cohorts to evaluate the monstrous potential of Cesalatamig, either as a standalone treatment or in combination with existing standard care options.

More than 50 clinical sites in the U.S. and China are currently engaged in enrolling patients, with a major focus on recruitment from U.S. locations.

What is Cesalatamig?

Cesalatamig is not just any antibody; it is a unique PD-1/VEGF bispecific antibody that boasts an extraordinary affinity for PD-1 and, interestingly, demonstrates over 40 times greater affinity for VEGF compared to existing bevacizumab-based inhibitors. This high-level interaction places Cesalatamig as a contender for best-in-class status, particularly due to its cooperative action mechanisms within PD-1 and VEGF-rich tumor environments. Moreover, it is engineered with enhanced Fc-silencing modifications to prevent the depletion of PD-1 positive effector T cells, making it a promising candidate in cancer therapy.

About OncoC4

Headquartered in Rockville, Maryland, OncoC4 is a privately held biopharmaceutical entity dedicated to the discovery and innovative development of therapies addressing critical healthcare needs in cancer and immune diseases. The company's pipeline is rich with asset types that reflect a commitment to pioneering treatments targeting both established and new areas in oncology and immunology. Notably, alongside Cesalatamig, OncoC4 is working on the first-in-class anti-SIGLEC-10 antibody, ONC-841, which is currently in a Phase 2 trial for various oncology and Phase 1 trials for neurodegenerative conditions.

Furthermore, OncoC4 maintains a strategic partnership with BioNTech to co-develop gotistobart (BNT316/ONC-392), a candidate targeting CTLA-4 with precise action against solid tumors, bolstering OncoC4's promise in the oncology landscape.

For further insights about OncoC4 and its groundbreaking work, please visit www.oncoc4.com.

Conclusion

The FDA's Fast Track Designation for Cesalatamig marks a pivotal moment for patients awaiting new treatment options for NSCLC and reflects OncoC4's dedication to transforming cancer therapy. With continued clinical trials and advancements, OncoC4 positions itself at the forefront of innovative cancer care, driving hope for many patients globally.